CANNABIDIOL

Brand name:

• Epidyolex®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Lennox-Gastaut syndrome Dravet syndrome

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New listing (Major)

Comment:

--

Submission sponsor:

Emerge Health Pty Ltd

Other PBAC consideration:

• CANNABIDIOL

Submission received for::

November 2020 PBAC meeting

Opportunity for consumer comment:

Open 29/04/2020 and close 10/06/2020 (see PBS Website)

PBAC meeting:

Held on 04/11/2020

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

18/12/2020

Lodgement of required documentation:

12/01/2021

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 28/01/2021

Status:

Finalised

Government processes:

Commenced on 11/03/2021

Medicine listed on the PBS:

01/05/2021 (see PBS schedule)

---